Denali Therapeutics Company
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Investors
Industry:
Biotechnology, Genetics, Health Diagnostics, Therapeutics
Last Funding Date:
2016
Investors Number:
8
Last Funding Type:
Series B
Headquarters:
UK
Founded Date:
2015
Funding Status:
IPO
Total Funding:
347000000
Estimated Revenue:
$10M to $50M
Employee Number:
251-500